-
Something wrong with this record ?
Trehalose in ophthalmology
C. Cejka, S. Kubinova, J. Cejkova,
Language English Country Spain
Document type Journal Article, Review
Grant support
LO1309
Ministry of Education, Youth and Sports of the Czech Republic
PubMed
30623968
DOI
10.14670/hh-18-082
Knihovny.cz E-resources
- MeSH
- Anti-Inflammatory Agents chemistry pharmacology MeSH
- Antioxidants chemistry pharmacology MeSH
- Apoptosis * MeSH
- Wound Healing * MeSH
- Clinical Trials as Topic MeSH
- Rabbits MeSH
- Humans MeSH
- Disease Models, Animal MeSH
- Ophthalmology MeSH
- Oxidative Stress * MeSH
- Cornea drug effects radiation effects MeSH
- Dry Eye Syndromes drug therapy MeSH
- Trehalose chemistry pharmacology MeSH
- Ultraviolet Rays MeSH
- Animals MeSH
- Check Tag
- Rabbits MeSH
- Humans MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Review MeSH
Trehalose, a disaccharide of glucose, is a naturally occurring nontoxic and nonreducing bioactive sugar. Trehalose is synthetized by many organisms when cells are exposed to stressful conditions, including dehydration, heat, oxidation, hypoxia or even anoxia. Although trehalose is not synthesized by mammalian cells, it has recently been demonstrated to have a number of important properties that indicate its utility in humans. Trehalose enables wound healing by protecting cells, especially cell membranes, from oxidative injury and dessication. When the injured cornea is treated with trehalose, corneal inflammation, scar formation and corneal neovascularization are suppressed. In dry eye disease, trehalose decreased cell apoptosis and reduced oxidative, inflammatory and proteolytic activity at the ocular surface. In UVB irradiated cornea, trehalose suppressed photodamage evoked by UVB rays. It decreased the intracorneal inflammation and reduced corneal neovascularization. Trehalose prevented postoperative fibrous scar formation after ocular surgery, such as glaucoma filtration surgery. The non-toxicity of trehalose allows its administration in humans for extended periods and enables its use in various disease states.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20006661
- 003
- CZ-PrNML
- 005
- 20200526105008.0
- 007
- ta
- 008
- 200511s2019 sp f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.14670/HH-18-082 $2 doi
- 035 __
- $a (PubMed)30623968
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sp
- 100 1_
- $a Cejka, Cestmir $u Institute of Experimental Medicine, Czech Academy of Sciences, Prague, Czech Republic.
- 245 10
- $a Trehalose in ophthalmology / $c C. Cejka, S. Kubinova, J. Cejkova,
- 520 9_
- $a Trehalose, a disaccharide of glucose, is a naturally occurring nontoxic and nonreducing bioactive sugar. Trehalose is synthetized by many organisms when cells are exposed to stressful conditions, including dehydration, heat, oxidation, hypoxia or even anoxia. Although trehalose is not synthesized by mammalian cells, it has recently been demonstrated to have a number of important properties that indicate its utility in humans. Trehalose enables wound healing by protecting cells, especially cell membranes, from oxidative injury and dessication. When the injured cornea is treated with trehalose, corneal inflammation, scar formation and corneal neovascularization are suppressed. In dry eye disease, trehalose decreased cell apoptosis and reduced oxidative, inflammatory and proteolytic activity at the ocular surface. In UVB irradiated cornea, trehalose suppressed photodamage evoked by UVB rays. It decreased the intracorneal inflammation and reduced corneal neovascularization. Trehalose prevented postoperative fibrous scar formation after ocular surgery, such as glaucoma filtration surgery. The non-toxicity of trehalose allows its administration in humans for extended periods and enables its use in various disease states.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a antiflogistika $x chemie $x farmakologie $7 D000893
- 650 _2
- $a antioxidancia $x chemie $x farmakologie $7 D000975
- 650 12
- $a apoptóza $7 D017209
- 650 _2
- $a klinické zkoušky jako téma $7 D002986
- 650 _2
- $a rohovka $x účinky léků $x účinky záření $7 D003315
- 650 _2
- $a modely nemocí na zvířatech $7 D004195
- 650 _2
- $a syndromy suchého oka $x farmakoterapie $7 D015352
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a oftalmologie $7 D009885
- 650 12
- $a oxidační stres $7 D018384
- 650 _2
- $a králíci $7 D011817
- 650 _2
- $a trehalosa $x chemie $x farmakologie $7 D014199
- 650 _2
- $a ultrafialové záření $7 D014466
- 650 12
- $a hojení ran $7 D014945
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Kubinova, Sarka $u Institute of Experimental Medicine, Czech Academy of Sciences, Prague, Czech Republic.
- 700 1_
- $a Cejkova, Jitka $u Institute of Experimental Medicine, Czech Academy of Sciences, Prague, Czech Republic. cejkova@biomed.cas.cz.
- 773 0_
- $w MED00005439 $t Histology and histopathology $x 1699-5848 $g Roč. 34, č. 6 (2019), s. 611-618
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/30623968 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20200511 $b ABA008
- 991 __
- $a 20200526105004 $b ABA008
- 999 __
- $a ok $b bmc $g 1525519 $s 1096717
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 34 $c 6 $d 611-618 $e 20190109 $i 1699-5848 $m Histology and histopathology $n Histol Histopathol $x MED00005439
- GRA __
- $a LO1309 $p Ministry of Education, Youth and Sports of the Czech Republic
- LZP __
- $a Pubmed-20200511